Paul Shitabata

Paul Shitabata

Auto-generated profile, based on publicly available information

Paul Shitabata

Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2022 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
SUSanusi Umar
Sanusi Umar
JLJenna J Lullo
Jenna J Lullo
MCMarissa Carter
Marissa Carter
PSPaul K Shitabata
Paul K Shitabata
DLDelphine Lee
Delphine Lee
Purpose: Both acne keloidalis nuchae (AKN) and cutis verticis gyrata (CVG) are scalp conditions predominantly affecting men. Both are characterized by dermal thickening and fibroblast hyperactivity. AKN typically occurs in the nuchal area, often involving the naturally occurring folds in the occipital region. The aim of this study was to determine the relationship between excessive scalp folding (CVG) and AKN. Patients and methods: A total of 108 patients with AKN seen over 11 years from July 2009 and November 2020 were retrospectively evaluated. Patients with AKN concomitant with CVG were selected for analysis. Results: Seven of the 108 AKN patients had scalp-wide (widespread) AKN lesions, including 4 with CVG. In 3 of the 4 patients with concomitant AKN and CVG, the AKN was widespread, and its onset had preceded CVG by 1– 2 years. In the fourth CVG patient, AKN lesions were confined to the nuchal area, and the CVG preceded AKN onset by several years. All patients were male, with a mean age of 35.8 years (overall) and 38.0 years (CVG group). Conclusion: We describe a previously unreported relationship between widespread AKN and CVG, with the development of AKN preceding CVG formation.

1 June 2022 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
SUSanusi Umar
Sanusi Umar
PSPaul Shitabata
Paul Shitabata
PRPaul Rose
Paul Rose
MCMarissa Carter
Marissa Carter
RTRattapon Thuangtong
Rattapon Thuangtong
MMMiguel Marti
Miguel Marti
Introduction: The difficulty of the follicular unit excision (FUE) hair transplantation procedure is currently attributed to hair curliness and subsurface angulation. Patients possessing the curliest hair shafts are considered the most challenging. Consequently, patients with these features are often denied FUE. However, this practice does not consider intrapatient variation in the graft attrition rate and the rates themselves, which are frequently low in very curly hair where the skin firmness/thickness is average. To better aid practitioners in predicting FUE performance, we have developed a new scoring system (the Sanusi FUE Score Scale [SFS Scale]) based on two major donor variables (hair and skin characteristics). Material and Method: The scale assigns scores to each of three hair subtypes (straight-wavy, curly, and coily-kinky) and each of three skin subtypes (thick/firm, soft/thin, and medium thickness/firmness). The scores were weighted based on the assessment of 13 experienced FUE practitioners from around the globe, who were asked to score each of the three skin and hair characteristics for their contribution to FUE difficulty. Results: On the contribution of skin characteristics to FUE difficulty, 12/13 (92%) practitioners assigned the highest (most difficult) score to thick/firm skin, with medium skin thickness/firmness being the least challenging. The same percentage of practitioners gave the highest difficulty score to coiled-kinky hair subtypes regarding the contribution of hair characteristics to FUE difficulty. All agreed that straight-wavy hair presents the least challenge to FUE performance. Tallying the scores of the skin and hair variables generates a final score range of 2– 9, which is associated with five grades/classes of challenge in the FUE procedure, influencing the need for a specialized skill/nuanced approach or equipment. Conclusion: We developed a universal FUE donor scoring scale that accounts for the diversity of human hair and skin types. Further evaluation to determine the validity of this new classification system in predicting and grading FUE difficulty and patient outcomes is warranted.

1 September 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
SUSanusi Umar
Sanusi Umar
AWAde Waterman
Ade Waterman
DTDonna Ton
Donna Ton
PSPaul Shitabata
Paul Shitabata
Purpose: Folliculitis decalvans (FD) is a difficult-to-treat, localized scarring alopecia characterized by an expanding area of chronically inflamed purulent plaques or masses. Current treatment modalities vary and often result in only temporary remission. There are no reports of surgical therapies for FD. Here, we describe FD treatment using surgical excision and second-intention healing aided by guarded high-tension sutures. Methods: Five patients (one woman and four men) with histologically confirmed FD were treated by surgical lesion excision. All wounds were allowed to heal via second-intention. Guarded high-tension sutures were employed to minimize tissue tears while aiding and guiding wound contraction. Results: All wounds healed with a 47– 83% spatial contraction of the maximum wound diameters. Three patients healed entirely by second-intention, while two required a minor skin graft to close the wound completely. No disease recurrence was noted at 10– 24 months. Conclusion: Surgical excision with second-intention healing aided by guarded high-tension sutures effectively treated small and extensive FD lesions with no recurrence at long-term follow-up. To our knowledge, this is the first report of successful surgical treatment of FD. Plain Language Summary: Current treatment modalities of folliculitis decalvans, including steroids, antibiotics, and isotretinoin, are suboptimal, typically resulting in recurrence following the withdrawal of treatments. In this case series, we report a first account of treatment success of refractory folliculitis decalvans using surgical excision with second intention healing aided by guarded high-tension suturing. The outpatient procedure resulted in long-term remission at 10– 24 months follow-up.

1 August 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
SUSanusi Umar
Sanusi Umar
DTDonna Ton
Donna Ton
MCMarissa Carter
Marissa Carter
PSPaul Shitabata
Paul Shitabata
Purpose: Small observational studies suggest subclinical disease occurrence in the normal-appearing scalp zones of several primary cicatricial alopecias. To aid patient management, we began routinely evaluating the entire scalp of patients with acne keloidalis nuchae (AKN), including trichoscopy-guided biopsies. Patients and Methods: This retrospective study evaluated 41 patients sequentially presenting with AKN at a single clinic between June and December 2022. Primary lesions and normal-appearing scalp in the superior parietal scalp at least 5 cm away from AKN-affected zones were clinically evaluated, and areas showing perifollicular erythema or scales/casts on trichoscopy were biopsied and histologically analyzed. Results: Forty-one men with AKN, including 20 men of African descent, 17 Hispanic, and 4 European-descended Whites, were evaluated. All patients, including 22% with associated folliculitis decalvans, showed scalp-wide trichoscopy signs of perifollicular erythema or scaling in normal-appearing scalp areas. All patients showed histologic evidence of perifollicular infundibulo-isthmic lymphocytoplasmic infiltrates and fibrosis (PIILIF), with 96% showing Vellus or miniaturized hair absence. PIILIF was often clinically mistaken for seborrheic dermatitis (44– 51%). All White patients had mild papular acne keloidalis nuchae lesions mistaken for seborrheic dermatitis. Conclusion: PIILIF may be a precursor to a wide spectrum of primary cicatricial alopecias, including AKN and folliculitis decalvans. This finding carries implications for the early diagnosis and management of AKN and other primary cicatricial alopecias. Plain Language Summary: Acne keloidalis nuchae (AKN) is a type of hair loss and scalp condition marked by scarring and inflammation. This condition falls under a group of chronic hair and scalp issues known as primary cicatricial alopecia (PCA). Current treatments for AKN and similar PCAs often do not work well, and the condition tends to return. We have found a hidden scalp condition that could be causing AKN and other PCAs. It’s a subtle disease that affects the entire scalp, even though it might not show noticeable symptoms. We have observed this condition in all 41 AKN patients in our study, and it’s characterized by certain changes in the hair and scalp’s structure and immune system response. Other studies have linked this condition to various other PCAs. We believe this hidden condition could be causing AKN and making it come back after treatment. This study suggests that treating AKN might require a broader approach beyond just treating the visible symptoms. Since this hidden condition exists in other PCAs, it might be a common cause.

1 April 2022 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
SUSanusi Umar
Sanusi Umar
PKPetrina Kan
Petrina Kan
MCMarissa J Carter
Marissa J Carter
PSPaul Shitabata
Paul Shitabata
Purpose: Central centrifugal cicatricial alopecia (CCCA) is the most common cause of scarring alopecia in women of African descent. However, current treatments for CCCA, such as immunosuppressants and immunomodulatory pharmaceutical agents, have suboptimal efficacy and undesirable side effects. This case series reports the therapeutic effect of a new botanical formulation (Dr. UGro Gashee) in four patients with histologically supported diagnoses of CCCA. The formulations contain at least three phytoactive ingredients that affect multiple targets in the cascade of pathophysiologic events contributing to CCCA. Possible mechanisms of action include anti-inflammatory effects, inhibiting proinflammatory cytokines, and the net antifibrotic effect of inhibiting transforming growth factor-beta while upregulating AMP-activated protein kinase and peroxisome proliferator-associated receptor-gamma activity. Patients and Methods: Four African American women with treatment-refractory CCCA were treated with a new topical botanical formula (cosmeceutical) alone or in combination with its oral formulation (nutraceutical) for 8 weeks to 1 year. The cosmeceutical and nutraceutical treatments contain similar phytoactive ingredient profiles. Treatment outcomes were collected using documented patient reports and images and by direct observation. Results: In all patients, scalp pruritus cessation occurred within 2 weeks of treatment, and significant hair regrowth was observed within 2 months. All patients reported a high satisfaction level without adverse effects. Conclusion: Patients with treatment-refractory CCCA responded to the novel botanical treatment reported in this study. Further evaluations in a controlled trial with more patients are warranted.

1 January 2026 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
SUSanusi Umar
Sanusi Umar
BTBelinda H Tan
Belinda H Tan
PSPaul K Shitabata
Paul K Shitabata
Introduction: Androgenetic alopecia (AGA) is traditionally regarded as a noninflammatory, androgen-driven condition. Yet clinical and histologic evidence identifies a subset of patients with perifollicular infundibulo-isthmic lymphocytic infiltrates and fibrosis (PIILIF), a histopathologic pattern resembling early primary cicatricial alopecia (PCA). This study evaluates the clinical, histologic, and immunophenotypic features of PIILIF and their diagnostic and therapeutic implications. Methods: This retrospective study of 129 AGA patients drawn from a referral center, obtained trichoscopy-guided biopsies from balding and clinically non-alopecic scalp (cNAS). Histopathologic and immunohistochemical findings were correlated with clinical features and treatment outcomes. Patients with PIILIF received multimodal therapy targeting androgenic and inflammatory pathways. The cohort, from a specialty clinic, included both typical and treatment-resistant AGA. Results: PIILIF was identified in the cNAS of 81% of patients, particularly in those aged 44 or older, with Norwood stage ≥ 5, or with prior poor response to therapy. Histology showed CD117+ mast cells, perifollicular CD4-predominant lymphocytes and fibrosis in the infundibulo-isthmic unit. Combination therapy using dihydrotestosterone blockade plus anti-inflammatory agents modeled after PCA therapies, including tetracyclines, topical calcineurin inhibitors, and select phytoactive botanicals, yielded greater improvement than standard AGA treatment regimens alone. Overall, 67% improved, and 2% had suboptimal outcomes (p < 0.0001). These findings support an AGA-PIILIF continuum that may include fibrosing alopecia in a pattern distribution. Conclusion: PIILIF represents an under‑recognized inflammatory endotype within AGA that may account for treatment resistance in some patients. Early biopsy can confirm the diagnosis, and therapy targeting hormonal and immune pathways may improve outcomes. Routine trichoscopy with a low threshold to biopsy perifollicularly abnormal units showing mild erythema, scale, or hyperpigmented collars can guide care, particularly in treatment resistant or equivocal cases. The broader systemic implications of this inflammatory signature merit further investigation. Plain Language Summary: Pattern hair loss is usually linked to hormones. Yet some people do not improve with standard treatment. We asked whether an immune type of inflammation, similar to what doctors see in scarring alopecias, might be present in these patients. We studied 129 adults with pattern hair loss. Using a magnified scalp exam, we took tiny skin samples from thinning areas and from nearby skin that looked normal. Most patients, 81%, had immune inflammation around the upper part of follicles with early scarring, even where the scalp looked normal. This differs from the mild, nonspecific inflammation sometimes seen in long-standing baldness. It was more common after age 44 and with advanced thinning. On magnified exam, a reddish ring, a darker ring in skin of color, or fine scale was common but not predictive, and redness faded with pressure. People did better when treatment targeted both hormones and this immune inflammation. The anti-inflammatory medicines were the same types used for scarring alopecias, such as tetracyclines, topical calcineurin inhibitors, and selected botanical agents, together with blockers of dihydrotestosterone. Overall, 67% improved, and 2% had a poor result. What this means is that an immune, scarring-type process can coexist with hormone-driven hair loss and may help explain treatment resistance in some patients. It also supports that, when treatment is not working or the exam is unclear, a biopsy can confirm the diagnosis and guide care. Early targeted therapy may improve outcomes.